<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571777</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2302</org_study_id>
    <secondary_id>2015-002899-25</secondary_id>
    <nct_id>NCT02571777</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma</brief_title>
  <official_title>A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial was to evaluate the efficacy and safety of two different doses of
      QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149
      doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics
      as determined by pulmonary function testing and effects on asthma control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study used a 52-week treatment, randomized, double-blind, double-dummy, parallel-group
      design. A total of 3092 asthma patients were randomized into the 5 treatment groups with a
      randomization ratio of 1:1:1:1:1 (approximately 617 patients per treatment group): QVM149
      150/50/80 μg once daily (o.d.), QVM149 150/50/160 μg o.d., QMF149 150/160 μg o.d. and QMF149
      150/320 μg o.d., all delivered via the Concept1 device, and salmeterol/fluticasone 50/500 μg
      twice daily (b.i.d.) delivered via Accuhaler. The 52 week treatment period was followed by a
      30-day Follow-up.

      The primary objective of this study was to demonstrate superiority of either QVM149 150/50/80
      μg o.d. to QMF149 150/160 μg o.d. or QVM149 150/50/160 μg o.d. to QMF149 150/320 μg o.d in
      terms of trough Forced Expiratory Volume in One Second (Trough FEV1) (FEV1) at Week 26, all
      delivered via Concept1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">June 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
The primary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. compared with QMF149 150/160 μg o.d. both delivered via Concept1
QVM149 150/50/160 μg o.d. compared with QMF149 150/320 μg o.d. both delivered via Concept1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52</measure>
    <time_frame>26 weeks, 52 weeks</time_frame>
    <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
This secondary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®
QVM149 150/50/160 μg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <description>Percentage of days without rescue medication usage (100 μg salbutamol/90 μg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ ≥ 0.5 at Week 26 and Week 52</measure>
    <time_frame>26 weeks, 52 weeks</time_frame>
    <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalization for Asthma Exacerbation</measure>
    <time_frame>52 weeks on average, up to 416 days</time_frame>
    <description>Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation by Exacerbation Category</measure>
    <time_frame>52 weeks on average, up to 416 days</time_frame>
    <description>Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).
The exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Asthma Exacerbations by Exacerbation Category</measure>
    <time_frame>52 weeks</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in Days of Asthma Exacerbations by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation</measure>
    <time_frame>52 weeks on average, up to 416 days</time_frame>
    <description>Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ) at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FEV1 at Weeks 4 and 12</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3092</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>QVM149 150/50/160 µg o.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QVM149 150/50/80 µg o.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QMF149 150/320 µg o.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QMF149 150/160 µg o.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone 50/500 μg b.i.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVM149 150/50/160</intervention_name>
    <arm_group_label>QVM149 150/50/160 µg o.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVM149 150/50/80</intervention_name>
    <arm_group_label>QVM149 150/50/80 µg o.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QMF149 150/320</intervention_name>
    <arm_group_label>QMF149 150/320 µg o.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QMF149 150/160</intervention_name>
    <arm_group_label>QMF149 150/160 µg o.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol/fluticasone</intervention_name>
    <arm_group_label>Salmeterol/fluticasone 50/500 μg b.i.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior
             to Visit 1 (Screening).

          -  Patients who have used medium or high dose of ICS/LABA combinations for asthma for at
             least 3 months and at stable medium or high doses of ICS/LABA for at least 1 month
             prior to Visit 1.

          -  Patients must be symptomatic at screening despite treatment with mid or high stable
             doses of ICS/LABA. Patients with ACQ-7 score ≥ 1.5 at Visit 101 and at Visit 102
             (before randomization).

          -  Patients with documented history of at least one asthma exacerbation which required
             medical care from a physician, ER visit (or local equivalent structure) or
             hospitalization in the 12 months prior to Visit 1, and required systemic
             corticosteroid treatment.

          -  Pre-bronchodilator FEV1 of &lt; 80 % of the predicted normal value for the patient
             according to ATS/ERS guidelines after withholding bronchodilators at both visits 101
             and 102.

          -  Withholding period of bronchodilators prior to spirometry: SABA for ≥ 6 hrs, Twice
             daily LABA (or FDC of ICS/LABA) for ≥ 12 hrs, Once daily LABA (or FDC of ICS/LABA) for
             ≥ 24 hrs, SAMA for ≥ 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines
             for 24 hrs, .

          -  Washout period of each drug should be kept as close as possible as above and should
             not be longer. If longer washout period is needed due to scheduling issues, please
             contact Novartis Medical monitor.

          -  A one-time repeat of percentage predicated FEV1 (Pre-bronchodilator) at Visit 101
             and/or Visit 102 is allowed in an ad-hoc visit. Repeat of Visit 101 spirometry should
             be done in an ad-hoc visit to be scheduled on a date that would provide sufficient
             time to receive confirmation from the spirometry data central reviewer of the validity
             of the assessment before randomization. Run-in medication should be dispensed once
             spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 %
             predicted normal value, and reversibility) as per equipment

          -  A one-time rescreen is allowed in case the patient fails to meet the criteria at the
             repeat, provided the patient returned to the required treatment as per inclusion
             criteria 4

          -  Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after
             administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit
             101.All patients must perform a reversibility test at Visit 101. If reversibility is
             not demonstrated at Visit 101 then one of the following criteria need to be met.

          -  Reversibility should be repeated once.

          -  Patients may be permitted to enter the study with historical evidence of reversibility
             that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.

          -  Alternatively, patients may be permitted to enter the study with a historical positive
             bronchoprovocation test that was performed within 2 years prior to Visit 1. If
             reversibility is not demonstrated at Visit 101 (or after repeated assessment in an
             ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not
             available (or was not performed according to the ATS/ERS guidelines patients must be
             screen failed

          -  Spacer devices are permitted during reversibility testing only. The Investigator or
             delegate may decide whether or not to use a spacer for the reversibility testing

        Exclusion Criteria:

          -  Patients who have had an asthma attack/exacerbation requiring systemic steroids or
             hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If
             patients experience an asthma attack/exacerbation requiring systemic steroids or
             hospitalization or emergency room visit between Visit 1 and Visit 102 they may be
             re-screened 6 weeks after recovery from the exacerbation.

          -  Patients who have ever required intubation for a severe asthma attack/exacerbation.

          -  Patients who have a clinical condition which is likely to be worsened by ICS
             administration (e.g. glaucoma, cataract and fragility fractures) who are according to
             investigator's medical judgment at risk participating in the study.

          -  Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).

          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or
             bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients
             who are stable on treatment can be considered).

          -  Patients who have had a respiratory tract infection or asthma worsening as determined
             by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and
             Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory
             tract infection or asthma worsening.

          -  Patients with evidence upon visual inspection (laboratory culture is not required) of
             clinically significant (in the opinion of investigator) oropharyngeal candidiasis at
             Visit 102 or earlier, with or without treatment. Patients may be re-screened once
             their candidiasis has been treated and has resolved.

          -  Patients with any chronic conditions affecting the upper respiratory tract (e.g.
             chronic sinusitis) which in the opinion of the investigator may interfere with the
             study evaluation or optimal participation in the study.

          -  Patients with a history of chronic lung diseases other than asthma, including (but not
             limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung
             disease, cystic fibrosis, clinically significant bronchiectasis and active
             tuberculosis.

          -  Patients with Type I diabetes or uncontrolled Type II diabetes.

          -  Patients who, either in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically significant condition such as (but not limited to)
             unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left
             ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease,
             psychiatric disease, neurodegenerative diseases, or other neurological disease,
             uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia,
             hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition
             that might compromise patient safety or compliance, interfere with evaluation, or
             preclude completion of the study.

          -  Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded.
             Patients with persistent atrial fibrillation as defined by continuous atrial
             fibrillation for at least 6 months and controlled with a rate control strategy (i.e.,
             selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or
             ablation therapy) for at least 6 months may be considered for inclusion. In such
             patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a
             resting ventricular rate &lt; 100/min. At Visit 101 the atrial fibrillation must be
             confirmed by central reading.

          -  Patients with a history of myocardial infarction (this should be confirmed clinically
             by the investigator) within the previous 12 months.

          -  Concomitant use of agents known to prolong the QT interval unless it can be
             permanently discontinued for the duration of study

          -  Patients with a history of long QT syndrome or whose QTc measured at Visit 101
             (Fridericia method) is prolonged (&gt; 450 msec for males and &gt; 460 msec for females) and
             confirmed by a central assessor (these patients should not be rescreened).

          -  Patients with a history of hypersensitivity to lactose, any of the study drugs or to
             similar drugs within the class including untoward reactions to sympathomimetic amines
             or inhaled medication or any component thereof.

          -  Patients who have not achieved an acceptable spirometry result at Visit 101 in
             accordance with ATS/ERS criteria for acceptability and repeatability. A one-time
             repeat spirometry is allowed in an ad-hoc visit scheduled as close as possible from
             the first attempt (but not on the same day) if the spirometry did not qualify due to
             ATS/ERS criteria at Visit 101 and/or Visit 102. If the patient fails the repeat
             assessment, the patient may be rescreened once, provided the patient returns to the
             required treatment as per inclusion criteria 4.

          -  Patients unable to use the Concept1 dry powder inhaler, Accuhaler or a metered dose
             inhaler. Spacer devices are not permitted.

          -  History of alcohol or other substance abuse.

          -  Patients with a known history of non-compliance to medication or who were unable or
             unwilling to complete a patient diary or who are unable or unwilling to use Electronic
             Peak Flow with e-diary device.

          -  Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night
             shift workers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nueve de Julio</city>
        <state>Buenos Aires</state>
        <zip>B6500EZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Nicolas</city>
        <state>Buenos Aires</state>
        <zip>B2900JUB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vicente Lopez</city>
        <state>Buenos Aires</state>
        <zip>B1602DOH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villa Maria</city>
        <state>Cordoba</state>
        <zip>X5900JKA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concepcion del Uruguay</city>
        <state>Entre Rios</state>
        <zip>3260</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godoy Cruz</city>
        <state>Mendoza</state>
        <zip>M5500EOB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <state>Rosario</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000JKR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000QID</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1646EBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1842DID</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CBA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parana</city>
        <zip>3100</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bludenz</city>
        <zip>6700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grieskirchen</city>
        <zip>4710</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gosselies</city>
        <state>BEL</state>
        <zip>6041</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <state>BEL</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braine L Alleud Waterloo</city>
        <zip>1420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eghezee</city>
        <zip>5310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erpent</city>
        <zip>5100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lebbeke</city>
        <zip>9280</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmedy</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <state>BGR</state>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8H 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valparaiso</city>
        <state>TX</state>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curico</city>
        <state>VII Region Del Maule</state>
        <zip>3341643</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>9100</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota DC</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <state>HRV</state>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrinja</city>
        <zip>44250</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zadar</city>
        <zip>23000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein Westfalen</state>
        <zip>D-44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koblenz</city>
        <state>NRW</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottbus</city>
        <state>Sachsen</state>
        <zip>03050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geesthacht</city>
        <state>Schleswig Holstein</state>
        <zip>12502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Annaberg-Buchholz</city>
        <zip>09456</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23558</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neu Isenburg</city>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rudersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>564 03</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>175 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion Crete</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budaors</city>
        <state>HUN</state>
        <zip>2040</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <state>HUN</state>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kapuvár</city>
        <state>HUN</state>
        <zip>9330</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puspokladany</city>
        <state>HUN</state>
        <zip>4150</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tata</city>
        <state>HUN</state>
        <zip>2890</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mateszalka</city>
        <zip>4700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>H-4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szigetszentmiklos</city>
        <zip>H-2310</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szigetvar</city>
        <zip>7900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guntur</city>
        <state>Andhra Pradesh</state>
        <zip>522 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>800014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dehli</city>
        <state>Delhi</state>
        <zip>110063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hubli</city>
        <state>Karnataka</state>
        <zip>580022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cherthala</city>
        <state>Kerala</state>
        <zip>688524</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>683 594</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>401107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashik</city>
        <state>Maharastra</state>
        <zip>422007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160 062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 045</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500 038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanpur</city>
        <state>Uttar Pradesh</state>
        <zip>208 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>DehraDun</city>
        <state>Uttarakhand</state>
        <zip>248001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Giborim, Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <zip>60127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kasuga-city</city>
        <state>Fukuoka</state>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro-city</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomakomai-city</city>
        <state>Hokkaido</state>
        <zip>053-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Himeji-city</city>
        <state>Hyogo</state>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>215-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>223-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236 0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokkaichi-city</city>
        <state>Mie</state>
        <zip>510-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki-city</city>
        <state>Okayama</state>
        <zip>712-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kishiwada-city</city>
        <state>Osaka</state>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <state>Shibuya Ku</state>
        <zip>150 0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamamatsu-city</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kokubunji-city</city>
        <state>Tokyo</state>
        <zip>185-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>145 0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima ku</city>
        <state>Tokyo</state>
        <zip>170 0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <state>JOR</state>
        <zip>11152</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <state>JOR</state>
        <zip>11183</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balvi</city>
        <state>LVA</state>
        <zip>4501</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bauska</city>
        <state>LVA</state>
        <zip>LV-3901</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <state>LVA</state>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jurmala</city>
        <state>LVA</state>
        <zip>LV-2015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rezekne</city>
        <state>LVA</state>
        <zip>LV-4600</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LVA</state>
        <zip>1021</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Chouf</city>
        <state>LBN</state>
        <zip>1503201002</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>166378</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <state>LTU</state>
        <zip>LT-04129</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LT</state>
        <zip>LT-50128</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <state>LT</state>
        <zip>01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-44320</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-45130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50154</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>06122</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacan</city>
        <state>MEX</state>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veracruz</city>
        <zip>91700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <state>CK</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lima</city>
        <zip>14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bulacan</city>
        <zip>3020</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ksawerow</city>
        <state>POL</state>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wejherowo</city>
        <state>POL</state>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aleksandrow Odzki</city>
        <zip>95-070</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Inowroclaw</city>
        <zip>88-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-445</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-853</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4100-180</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <state>ROM</state>
        <zip>200712</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deva</city>
        <state>ROM</state>
        <zip>330084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arad</city>
        <zip>310085</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bacau</city>
        <zip>600252</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasov</city>
        <zip>500086</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030317</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400139</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deva</city>
        <zip>330162</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125993</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perm</city>
        <zip>614056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perm</city>
        <zip>614068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pskov</city>
        <zip>180007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vladikavkaz</city>
        <zip>362019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188640</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kezmarok</city>
        <zip>060 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trencin</city>
        <zip>91101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berea</city>
        <state>Durban</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu Natal</state>
        <zip>4093</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kempton Park</city>
        <state>ZAF</state>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marbella</city>
        <state>Andalucia</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esparraguera</city>
        <state>Barcelona</state>
        <zip>08292</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laredo</city>
        <state>Cantabria</state>
        <zip>39770</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vila-real</city>
        <state>Castellon</state>
        <zip>12540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <state>Catalunya</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alzira</city>
        <state>Comunidad Valenciana</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caceres</city>
        <state>Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lidingo</city>
        <zip>181 58</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gossau</city>
        <zip>9200</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <state>Nonthaburi</state>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Yorkshire</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiltshire</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <state>VNM</state>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Jordan</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <results_first_submitted>June 12, 2020</results_first_submitted>
  <results_first_submitted_qc>July 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2020</results_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>QVM149</keyword>
  <keyword>QMF149</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02571777/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02571777/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in 415 investigative sites in 41 countries</recruitment_details>
      <pre_assignment_details>4851 participants were screened of which 3092 participants were randomized to 1 of the 5 treatment groups with a randomization ratio of 1:1:1:1:1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVM149 150/50/160 µg o.d.</title>
          <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="P2">
          <title>QVM149 150/50/80 µg o.d.</title>
          <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="P3">
          <title>QMF149 150/320 µg o.d.</title>
          <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="P4">
          <title>QMF149 150/160 µg o.d.</title>
          <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="P5">
          <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
          <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="619"/>
                <participants group_id="P2" count="620"/>
                <participants group_id="P3" count="618"/>
                <participants group_id="P4" count="617"/>
                <participants group_id="P5" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="615"/>
                <participants group_id="P2" count="616"/>
                <participants group_id="P3" count="611"/>
                <participants group_id="P4" count="607"/>
                <participants group_id="P5" count="612"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="616"/>
                <participants group_id="P2" count="617"/>
                <participants group_id="P3" count="613"/>
                <participants group_id="P4" count="608"/>
                <participants group_id="P5" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="582"/>
                <participants group_id="P3" count="577"/>
                <participants group_id="P4" count="580"/>
                <participants group_id="P5" count="582"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set (RAN) consisted of all participants who were assigned a randomization number, regardless of whether or not they actually received study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>QVM149 150/50/160 µg o.d.</title>
          <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="B2">
          <title>QVM149 150/50/80 µg o.d.</title>
          <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="B3">
          <title>QMF149 150/320 µg o.d.</title>
          <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="B4">
          <title>QMF149 150/160 µg o.d.</title>
          <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="B5">
          <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
          <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="619"/>
            <count group_id="B2" value="620"/>
            <count group_id="B3" value="618"/>
            <count group_id="B4" value="617"/>
            <count group_id="B5" value="618"/>
            <count group_id="B6" value="3092"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="12.91"/>
                    <measurement group_id="B2" value="52.4" spread="12.71"/>
                    <measurement group_id="B3" value="52.0" spread="12.81"/>
                    <measurement group_id="B4" value="51.8" spread="12.86"/>
                    <measurement group_id="B5" value="52.9" spread="12.23"/>
                    <measurement group_id="B6" value="52.2" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="380"/>
                    <measurement group_id="B4" value="378"/>
                    <measurement group_id="B5" value="417"/>
                    <measurement group_id="B6" value="1918"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="239"/>
                    <measurement group_id="B5" value="201"/>
                    <measurement group_id="B6" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="456"/>
                    <measurement group_id="B2" value="458"/>
                    <measurement group_id="B3" value="453"/>
                    <measurement group_id="B4" value="452"/>
                    <measurement group_id="B5" value="468"/>
                    <measurement group_id="B6" value="2287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="131"/>
                    <measurement group_id="B6" value="671"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
The primary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. compared with QMF149 150/160 μg o.d. both delivered via Concept1
QVM149 150/50/160 μg o.d. compared with QMF149 150/320 μg o.d. both delivered via Concept1.</description>
        <time_frame>26 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
The primary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. compared with QMF149 150/160 μg o.d. both delivered via Concept1
QVM149 150/50/160 μg o.d. compared with QMF149 150/320 μg o.d. both delivered via Concept1.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
                <count group_id="O2" value="614"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="602"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.050" spread="0.0128"/>
                    <measurement group_id="O2" value="2.029" spread="0.0129"/>
                    <measurement group_id="O3" value="1.984" spread="0.0129"/>
                    <measurement group_id="O4" value="1.953" spread="0.0130"/>
                    <measurement group_id="O5" value="1.930" spread="0.0131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>LS Mean</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52</title>
        <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control.</description>
        <time_frame>26 weeks, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52</title>
          <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="607"/>
                <count group_id="O2" value="595"/>
                <count group_id="O3" value="596"/>
                <count group_id="O4" value="598"/>
                <count group_id="O5" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="559"/>
                    <count group_id="O3" value="562"/>
                    <count group_id="O4" value="559"/>
                    <count group_id="O5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.542" spread="0.0329"/>
                    <measurement group_id="O2" value="1.543" spread="0.0330"/>
                    <measurement group_id="O3" value="1.528" spread="0.0329"/>
                    <measurement group_id="O4" value="1.614" spread="0.0331"/>
                    <measurement group_id="O5" value="1.628" spread="0.0329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="552"/>
                    <count group_id="O2" value="537"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="536"/>
                    <count group_id="O5" value="547"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.406" spread="0.0334"/>
                    <measurement group_id="O2" value="1.535" spread="0.0337"/>
                    <measurement group_id="O3" value="1.465" spread="0.0335"/>
                    <measurement group_id="O4" value="1.545" spread="0.0338"/>
                    <measurement group_id="O5" value="1.527" spread="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.729</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.066</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0404</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>-0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.151</ci_lower_limit>
            <ci_upper_limit>0.010</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.164</ci_lower_limit>
            <ci_upper_limit>-0.005</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0415</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.140</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0414</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.202</ci_lower_limit>
            <ci_upper_limit>-0.040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.814</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0420</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.845</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
This secondary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®
QVM149 150/50/160 μg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®</description>
        <time_frame>26 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
This secondary endpoint considered the following 2 comparison groups:
QVM149 150/50/80 μg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®
QVM149 150/50/160 μg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 μg b.i.d. via Accuhaler®</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
                <count group_id="O2" value="614"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="602"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.050" spread="0.0128"/>
                    <measurement group_id="O2" value="2.029" spread="0.0129"/>
                    <measurement group_id="O3" value="1.984" spread="0.0129"/>
                    <measurement group_id="O4" value="1.953" spread="0.0130"/>
                    <measurement group_id="O5" value="1.930" spread="0.0131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0177</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0177</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 at Week 52</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 at Week 52</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
                <count group_id="O2" value="614"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="602"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.050" spread="0.0129"/>
                    <measurement group_id="O2" value="1.992" spread="0.0130"/>
                    <measurement group_id="O3" value="1.965" spread="0.0130"/>
                    <measurement group_id="O4" value="1.930" spread="0.0130"/>
                    <measurement group_id="O5" value="1.905" spread="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0178</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0178</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0179</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12</title>
        <description>Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test.</description>
        <time_frame>4 weeks, 12 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12</title>
          <description>Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="594"/>
                <count group_id="O3" value="592"/>
                <count group_id="O4" value="596"/>
                <count group_id="O5" value="598"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="598"/>
                    <count group_id="O2" value="573"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="579"/>
                    <count group_id="O5" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.091" spread="0.0161"/>
                    <measurement group_id="O2" value="3.059" spread="0.0163"/>
                    <measurement group_id="O3" value="3.018" spread="0.0163"/>
                    <measurement group_id="O4" value="3.020" spread="0.0163"/>
                    <measurement group_id="O5" value="2.952" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="580"/>
                    <count group_id="O2" value="569"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="562"/>
                    <count group_id="O5" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.067" spread="0.0162"/>
                    <measurement group_id="O2" value="3.065" spread="0.0164"/>
                    <measurement group_id="O3" value="3.011" spread="0.0163"/>
                    <measurement group_id="O4" value="3.014" spread="0.0164"/>
                    <measurement group_id="O5" value="2.965" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0218</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0217</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0220</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0218</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0220</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks</title>
        <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks</title>
          <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>L/s</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
                <count group_id="O2" value="614"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="602"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.354" spread="0.0190"/>
                    <measurement group_id="O2" value="1.263" spread="0.0192"/>
                    <measurement group_id="O3" value="1.260" spread="0.0191"/>
                    <measurement group_id="O4" value="1.214" spread="0.0192"/>
                    <measurement group_id="O5" value="1.207" spread="0.0194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0254</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0256</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.049</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0256</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0258</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</title>
        <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
        <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</title>
          <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="596"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="581"/>
                <count group_id="O4" value="584"/>
                <count group_id="O5" value="586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 - Mean morning PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="583"/>
                    <count group_id="O3" value="581"/>
                    <count group_id="O4" value="584"/>
                    <count group_id="O5" value="584"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="1.93"/>
                    <measurement group_id="O2" value="40.5" spread="1.95"/>
                    <measurement group_id="O3" value="29.5" spread="1.95"/>
                    <measurement group_id="O4" value="25.6" spread="1.95"/>
                    <measurement group_id="O5" value="12.5" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 - Mean evening PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="594"/>
                    <count group_id="O2" value="584"/>
                    <count group_id="O3" value="580"/>
                    <count group_id="O4" value="578"/>
                    <count group_id="O5" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="1.87"/>
                    <measurement group_id="O2" value="34.7" spread="1.88"/>
                    <measurement group_id="O3" value="22.8" spread="1.88"/>
                    <measurement group_id="O4" value="20.6" spread="1.89"/>
                    <measurement group_id="O5" value="10.4" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 - Mean morning PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="584"/>
                    <count group_id="O3" value="581"/>
                    <count group_id="O4" value="583"/>
                    <count group_id="O5" value="586"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="2.03"/>
                    <measurement group_id="O2" value="41.2" spread="2.05"/>
                    <measurement group_id="O3" value="28.8" spread="2.05"/>
                    <measurement group_id="O4" value="25.6" spread="2.06"/>
                    <measurement group_id="O5" value="12.7" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 - Mean evening PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="577"/>
                    <count group_id="O3" value="578"/>
                    <count group_id="O4" value="576"/>
                    <count group_id="O5" value="578"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="1.97"/>
                    <measurement group_id="O2" value="35.0" spread="1.99"/>
                    <measurement group_id="O3" value="21.2" spread="1.99"/>
                    <measurement group_id="O4" value="20.1" spread="2.00"/>
                    <measurement group_id="O5" value="9.2" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear Mixed Model (LMM)</method>
            <param_type>LS Mean</param_type>
            <param_value>18.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>35.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.2</ci_lower_limit>
            <ci_upper_limit>40.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>14.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.8</ci_lower_limit>
            <ci_upper_limit>20.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>28.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.9</ci_lower_limit>
            <ci_upper_limit>33.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>16.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.8</ci_lower_limit>
            <ci_upper_limit>21.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>29.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.2</ci_lower_limit>
            <ci_upper_limit>34.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>14.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.1</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>24.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.3</ci_lower_limit>
            <ci_upper_limit>29.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>18.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.4</ci_lower_limit>
            <ci_upper_limit>24.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>34.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.5</ci_lower_limit>
            <ci_upper_limit>40.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>15.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>28.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.2</ci_lower_limit>
            <ci_upper_limit>33.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>17.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.3</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>29.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.2</ci_lower_limit>
            <ci_upper_limit>34.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>15.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.7</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52 - Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>25.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.5</ci_lower_limit>
            <ci_upper_limit>31.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="552"/>
                <count group_id="O3" value="559"/>
                <count group_id="O4" value="554"/>
                <count group_id="O5" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="1.35"/>
                    <measurement group_id="O2" value="18.0" spread="1.36"/>
                    <measurement group_id="O3" value="22.2" spread="1.36"/>
                    <measurement group_id="O4" value="18.0" spread="1.37"/>
                    <measurement group_id="O5" value="18.9" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.907</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.997</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.606</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="594"/>
                <count group_id="O2" value="577"/>
                <count group_id="O3" value="579"/>
                <count group_id="O4" value="579"/>
                <count group_id="O5" value="578"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="1.32"/>
                    <measurement group_id="O2" value="17.9" spread="1.34"/>
                    <measurement group_id="O3" value="21.8" spread="1.33"/>
                    <measurement group_id="O4" value="18.0" spread="1.34"/>
                    <measurement group_id="O5" value="18.8" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.943</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.612</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="582"/>
                <count group_id="O4" value="584"/>
                <count group_id="O5" value="586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="1.11"/>
                    <measurement group_id="O2" value="17.6" spread="1.12"/>
                    <measurement group_id="O3" value="18.4" spread="1.13"/>
                    <measurement group_id="O4" value="16.1" spread="1.13"/>
                    <measurement group_id="O5" value="16.9" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.318</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="582"/>
                <count group_id="O4" value="584"/>
                <count group_id="O5" value="586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="1.33"/>
                    <measurement group_id="O2" value="18.5" spread="1.35"/>
                    <measurement group_id="O3" value="19.9" spread="1.35"/>
                    <measurement group_id="O4" value="15.5" spread="1.35"/>
                    <measurement group_id="O5" value="15.6" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.814</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks</title>
        <description>Percentage of days without rescue medication usage (100 μg salbutamol/90 μg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment.</description>
        <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks</title>
          <description>Percentage of days without rescue medication usage (100 μg salbutamol/90 μg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="590"/>
                <count group_id="O2" value="577"/>
                <count group_id="O3" value="578"/>
                <count group_id="O4" value="580"/>
                <count group_id="O5" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="590"/>
                    <count group_id="O2" value="577"/>
                    <count group_id="O3" value="578"/>
                    <count group_id="O4" value="580"/>
                    <count group_id="O5" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="1.32"/>
                    <measurement group_id="O2" value="19.5" spread="1.33"/>
                    <measurement group_id="O3" value="23.3" spread="1.33"/>
                    <measurement group_id="O4" value="18.2" spread="1.33"/>
                    <measurement group_id="O5" value="19.6" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="583"/>
                    <count group_id="O2" value="574"/>
                    <count group_id="O3" value="576"/>
                    <count group_id="O4" value="576"/>
                    <count group_id="O5" value="578"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="1.36"/>
                    <measurement group_id="O2" value="21.9" spread="1.36"/>
                    <measurement group_id="O3" value="24.9" spread="1.36"/>
                    <measurement group_id="O4" value="20.8" spread="1.37"/>
                    <measurement group_id="O5" value="21.8" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.645</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.517</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.956</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ ≥ 0.5 at Week 26 and Week 52</title>
        <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
        <time_frame>26 weeks, 52 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ ≥ 0.5 at Week 26 and Week 52</title>
          <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="559"/>
                    <count group_id="O3" value="562"/>
                    <count group_id="O4" value="559"/>
                    <count group_id="O5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="71.7"/>
                    <measurement group_id="O3" value="74.2"/>
                    <measurement group_id="O4" value="70.7"/>
                    <measurement group_id="O5" value="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="552"/>
                    <count group_id="O2" value="537"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="536"/>
                    <count group_id="O5" value="547"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="72.8"/>
                    <measurement group_id="O3" value="77.9"/>
                    <measurement group_id="O4" value="73.1"/>
                    <measurement group_id="O5" value="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.535</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.380</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.922</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalization for Asthma Exacerbation</title>
        <description>Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).</description>
        <time_frame>52 weeks on average, up to 416 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalization for Asthma Exacerbation</title>
          <description>Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).</description>
          <population>FAS</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.0" lower_limit="2" upper_limit="416"/>
                    <measurement group_id="O2" value="367.0" lower_limit="2" upper_limit="396"/>
                    <measurement group_id="O3" value="367.0" lower_limit="1" upper_limit="411"/>
                    <measurement group_id="O4" value="367.0" lower_limit="1" upper_limit="408"/>
                    <measurement group_id="O5" value="367.0" lower_limit="1" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.150</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>4.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation by Exacerbation Category</title>
        <description>Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).
The exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.</description>
        <time_frame>52 weeks on average, up to 416 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation by Exacerbation Category</title>
          <description>Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).
The exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.</description>
          <population>FAS</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.0" lower_limit="2" upper_limit="416"/>
                    <measurement group_id="O2" value="366.0" lower_limit="2" upper_limit="396"/>
                    <measurement group_id="O3" value="366.0" lower_limit="1" upper_limit="411"/>
                    <measurement group_id="O4" value="365.0" lower_limit="1" upper_limit="387"/>
                    <measurement group_id="O5" value="365.0" lower_limit="1" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.0" lower_limit="2" upper_limit="416"/>
                    <measurement group_id="O2" value="366.0" lower_limit="2" upper_limit="396"/>
                    <measurement group_id="O3" value="366.0" lower_limit="1" upper_limit="411"/>
                    <measurement group_id="O4" value="366.0" lower_limit="1" upper_limit="389"/>
                    <measurement group_id="O5" value="366.0" lower_limit="1" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate or severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.0" lower_limit="2" upper_limit="416"/>
                    <measurement group_id="O2" value="364.0" lower_limit="2" upper_limit="396"/>
                    <measurement group_id="O3" value="361.0" lower_limit="1" upper_limit="411"/>
                    <measurement group_id="O4" value="360.0" lower_limit="1" upper_limit="384"/>
                    <measurement group_id="O5" value="278.0" lower_limit="1" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.497</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Asthma Exacerbations by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>52 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Asthma Exacerbations by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS</population>
          <units>Exacerbations per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.39" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.58" lower_limit="0.50" upper_limit="0.67"/>
                    <measurement group_id="O3" value="0.54" lower_limit="0.47" upper_limit="0.63"/>
                    <measurement group_id="O4" value="0.67" lower_limit="0.58" upper_limit="0.77"/>
                    <measurement group_id="O5" value="0.72" lower_limit="0.63" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.22" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.32" upper_limit="0.45"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.28" upper_limit="0.39"/>
                    <measurement group_id="O4" value="0.41" lower_limit="0.35" upper_limit="0.48"/>
                    <measurement group_id="O5" value="0.45" lower_limit="0.39" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate, severe) asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.64" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.75" upper_limit="0.98"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.82" upper_limit="1.06"/>
                    <measurement group_id="O4" value="0.98" lower_limit="0.86" upper_limit="1.11"/>
                    <measurement group_id="O5" value="1.23" lower_limit="1.08" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Generalized linear modeñ</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.531</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>Linear generalized model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration in Days of Asthma Exacerbations by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Duration in Days of Asthma Exacerbations by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="10.73"/>
                    <measurement group_id="O2" value="5.6" spread="12.87"/>
                    <measurement group_id="O3" value="6.7" spread="20.52"/>
                    <measurement group_id="O4" value="7.1" spread="17.17"/>
                    <measurement group_id="O5" value="8.1" spread="20.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="7.31"/>
                    <measurement group_id="O2" value="4.1" spread="11.18"/>
                    <measurement group_id="O3" value="4.9" spread="19.07"/>
                    <measurement group_id="O4" value="4.5" spread="10.54"/>
                    <measurement group_id="O5" value="5.8" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate, severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="16.02"/>
                    <measurement group_id="O2" value="8.1" spread="20.51"/>
                    <measurement group_id="O3" value="10.7" spread="28.70"/>
                    <measurement group_id="O4" value="9.6" spread="21.76"/>
                    <measurement group_id="O5" value="12.8" spread="29.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.183</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="35.9"/>
                    <measurement group_id="O5" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="23.2"/>
                    <measurement group_id="O4" value="27.3"/>
                    <measurement group_id="O5" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate, severe) asthma exacerbation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="615"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="607"/>
                    <count group_id="O5" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="40.2"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="44.0"/>
                    <measurement group_id="O5" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation</title>
        <description>Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event.</description>
        <time_frame>52 weeks on average, up to 416 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation</title>
          <description>Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event.</description>
          <population>FAS</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.0" lower_limit="11" upper_limit="416"/>
                    <measurement group_id="O2" value="367.0" lower_limit="2" upper_limit="399"/>
                    <measurement group_id="O3" value="367.0" lower_limit="3" upper_limit="411"/>
                    <measurement group_id="O4" value="367.0" lower_limit="2" upper_limit="408"/>
                    <measurement group_id="O5" value="367.0" lower_limit="2" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.566</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations</title>
        <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations</title>
          <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
          <population>FAS</population>
          <units>prednisone-equivalent milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="607"/>
                <count group_id="O5" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" spread="169.76"/>
                    <measurement group_id="O2" value="72.0" spread="211.41"/>
                    <measurement group_id="O3" value="73.2" spread="235.90"/>
                    <measurement group_id="O4" value="82.5" spread="208.36"/>
                    <measurement group_id="O5" value="86.0" spread="199.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks</title>
        <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
        <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks</title>
          <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="590"/>
                <count group_id="O2" value="577"/>
                <count group_id="O3" value="578"/>
                <count group_id="O4" value="580"/>
                <count group_id="O5" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="590"/>
                    <count group_id="O2" value="577"/>
                    <count group_id="O3" value="578"/>
                    <count group_id="O4" value="580"/>
                    <count group_id="O5" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="1.32"/>
                    <measurement group_id="O2" value="19.5" spread="1.33"/>
                    <measurement group_id="O3" value="23.3" spread="1.33"/>
                    <measurement group_id="O4" value="18.2" spread="1.33"/>
                    <measurement group_id="O5" value="19.6" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="583"/>
                    <count group_id="O2" value="574"/>
                    <count group_id="O3" value="576"/>
                    <count group_id="O4" value="576"/>
                    <count group_id="O5" value="578"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="1.36"/>
                    <measurement group_id="O2" value="21.9" spread="1.36"/>
                    <measurement group_id="O3" value="24.9" spread="1.36"/>
                    <measurement group_id="O4" value="20.8" spread="1.37"/>
                    <measurement group_id="O5" value="21.8" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.645</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>LMM</method>
            <param_type>LMM</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>LMM</method>
            <param_type>LMM</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.517</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.956</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ) at Week 52</title>
        <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.</description>
        <time_frame>52 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ) at Week 52</title>
          <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="593"/>
                <count group_id="O3" value="595"/>
                <count group_id="O4" value="599"/>
                <count group_id="O5" value="594"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.555" spread="0.0354"/>
                    <measurement group_id="O2" value="5.445" spread="0.0358"/>
                    <measurement group_id="O3" value="5.535" spread="0.0356"/>
                    <measurement group_id="O4" value="5.499" spread="0.0358"/>
                    <measurement group_id="O5" value="5.495" spread="0.0357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.690</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0502</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.060</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0502</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0506</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.153</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.319</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0505</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.150</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose FEV1 at Weeks 4 and 12</title>
        <description>Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>4 weeks, 12 weeks</time_frame>
        <population>FAS including patients with a valid measurement for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FEV1 at Weeks 4 and 12</title>
          <description>Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS including patients with a valid measurement for the outcome measure.</population>
          <units>litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="594"/>
                <count group_id="O3" value="592"/>
                <count group_id="O4" value="596"/>
                <count group_id="O5" value="598"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="598"/>
                    <count group_id="O2" value="573"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="579"/>
                    <count group_id="O5" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.032" spread="0.0122"/>
                    <measurement group_id="O2" value="1.983" spread="0.0123"/>
                    <measurement group_id="O3" value="1.963" spread="0.0124"/>
                    <measurement group_id="O4" value="1.950" spread="0.0123"/>
                    <measurement group_id="O5" value="1.887" spread="0.0123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="580"/>
                    <count group_id="O2" value="569"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="562"/>
                    <count group_id="O5" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.024" spread="0.0134"/>
                    <measurement group_id="O2" value="1.994" spread="0.0135"/>
                    <measurement group_id="O3" value="1.966" spread="0.0135"/>
                    <measurement group_id="O4" value="1.944" spread="0.0136"/>
                    <measurement group_id="O5" value="1.907" spread="0.0135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0166</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0165</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0167</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0166</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0183</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0185</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>MMRM</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</title>
        <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 150/50/160 µg o.d.</title>
            <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>QVM149 150/50/80 µg o.d.</title>
            <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O3">
            <title>QMF149 150/320 µg o.d.</title>
            <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O4">
            <title>QMF149 150/160 µg o.d.</title>
            <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
            <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</title>
          <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
          <population>SAF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="616"/>
                <count group_id="O2" value="617"/>
                <count group_id="O3" value="613"/>
                <count group_id="O4" value="608"/>
                <count group_id="O5" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days (52 weeks on average, up to 416 days).</time_frame>
      <desc>Any signs or symptoms that occurs during study treatment plus the 30 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>QVM149 150/50/160 μg o.d.</title>
          <description>QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="E2">
          <title>QVM149 150/50/80 μg o.d.</title>
          <description>QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="E3">
          <title>QMF149 150/320 μg o.d.</title>
          <description>QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="E4">
          <title>QMF149 150/160 μg o.d.</title>
          <description>QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device</description>
        </group>
        <group group_id="E5">
          <title>Salmeterol/Fluticasone 50/500 μg b.i.d.</title>
          <description>Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cardiac event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Primary biliary cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Jaw disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Soft tissue sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Aortic dissection rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Haemorrhagic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="367" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="387" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="377" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="392" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="419" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="249" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="265" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="306" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="618"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="617"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="613"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="608"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="618"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

